GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TFF Pharmaceuticals Inc (NAS:TFFP) » Definitions » EBITDA

TFF Pharmaceuticals (TFF Pharmaceuticals) EBITDA : $-21.39 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is TFF Pharmaceuticals EBITDA?

TFF Pharmaceuticals's EBITDA for the three months ended in Dec. 2023 was $-5.24 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.39 Mil.

During the past 3 years, the average EBITDA Growth Rate was -4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of TFF Pharmaceuticals was -4.60% per year. The lowest was -370.90% per year. And the median was -37.90% per year.

TFF Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2023 was $-2.21. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.66.

During the past 3 years, the average EBITDA per Share Growth Rate was 19.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of TFF Pharmaceuticals was 19.50% per year. The lowest was -350.10% per year. And the median was 15.50% per year.


TFF Pharmaceuticals EBITDA Historical Data

The historical data trend for TFF Pharmaceuticals's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TFF Pharmaceuticals EBITDA Chart

TFF Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Get a 7-Day Free Trial -11.99 -18.69 -31.68 -31.41 -21.39

TFF Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.26 -6.96 -4.90 -4.30 -5.24

Competitive Comparison of TFF Pharmaceuticals's EBITDA

For the Biotechnology subindustry, TFF Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TFF Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TFF Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where TFF Pharmaceuticals's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

TFF Pharmaceuticals's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

TFF Pharmaceuticals's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, TFF Pharmaceuticals's EBITDA was $-21.39 Mil.

TFF Pharmaceuticals's EBITDA for the quarter that ended in Dec. 2023 is calculated as

TFF Pharmaceuticals's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, TFF Pharmaceuticals's EBITDA was $-5.24 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

TFF Pharmaceuticals  (NAS:TFFP) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


TFF Pharmaceuticals EBITDA Related Terms

Thank you for viewing the detailed overview of TFF Pharmaceuticals's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


TFF Pharmaceuticals (TFF Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
Executives
Carlson Capital L P 10 percent owner 2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201
Clint Duane Carlson 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Zamaneh Mikhak officer: Chief Medical Officer 1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107
Robert S Mills director 8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812
Kirk Allen Coleman officer: CFO, Secretary, and Treasurer 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Asgard Investment Corp. Ii 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Double Black Diamond Offshore Ltd 10 percent owner CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Brandi Roberts director 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Glenn R. Mattes director, officer: President and CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Malcolm Fairbairn director C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563
Lung Therapeutics, Inc. 10 percent owner P.O. BOX 150183, AUSTIN TX 78715

TFF Pharmaceuticals (TFF Pharmaceuticals) Headlines

From GuruFocus

Is TFF Pharmaceuticals Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 12-19-2022